No decision has been made yet on whether the announced meeting between the US and Russian presidents in Budapest will take place, Donald Trump <a href="https://www.youtube.com/watch?v=qM_CtA2VLFc">said </a>in response to questions from reporters.

'Don't want to waste time': Trump says decision on meeting with Putin not yet made

Alphabet Inc.

The new browser could tug some of the users of Google Chrome, which is Alphabet's main source of revenue

OpenAI unveiled its own browser. Shares of Google's parent company fell

Warner Bros. Discovery, Inc.

Media conglomerate Warner Bros. Discovery<a href="https://www.prnewswire.com/news-releases/warner-bros-discovery-initiates-review-of-potential-alternatives-to-maximize-shareholder-value-302590176.html?utm_source=chatgpt.com"> said</a> it is considering a full sale of the business due to interest from potential buyers. Among the interested parties may include Netflix and Comcast,<a href="https://www.cnbc.com/2025/10/21/wbd-sale-warner-bros-media.html#:~:text=Netflix,CNBC%E2%80%99s%20David%20Faber."> notes</a> CNBC citing sources. It was previously reported that Paramount Skydance head David Ellison is also in talks to buy Warner Bros. In October, Warner Bros. Discovery rejected Paramount's initial offer of about $20 per share, deeming it too low, Bloomberg<a href="https://www.bloomberg.com/news/articles/2025-10-12/warner-bros-is-said-to-rebuff-paramount-takeover-approach?utm_source=chatgpt.com"> wrote</a>.

Warner Bros. is considering a full sale of the company. Shares soared 12%

At the same time, it became known that Trump has no plans to meet with Putin "in the near future"

Europe and Ukraine are preparing a proposal to end the war. It contains 12 points

General Motors Company

The automaker is strengthening its position in the U.S. domestic market and getting a boost from the Trump administration's policies

General Motors improves outlook, stock has best growth in five years. Is it worth buying?

Newmont Corporation

Royal Gold, Inc.

Barrick Mining Corporation

Gold showed the strongest decline since April 2013, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-10-21/gold-and-silver-post-steepest-drops-in-years-amid-market-selloff?srnd=homepage-europe&amp;sref=Y0jVLcFo">reports </a>. The cost of metal on the spot market fell to $4082 per ounce, losing more than 6%.

Gold has its worst collapse since 2013. Investors sell off mining companies

Investment guru offered those willing to participate in testing

'Digital Ray': billionaire Ray Dalio to launch AI clone to dispense advice

In trading on October 21, the cost of gold <a href="https://www.bloomberg.com/quote/XAU:CUR">fell</a> more than 4% to $4168.07 per troy ounce. This was the strongest decline over the past four years after several weeks of rapid growth, <a href="https://www.bloomberg.com/news/articles/2025-10-20/gold-s-record-busting-rally-resumes-after-dip-buyers-emerge">noted</a> Bloomberg.

Gold posted its biggest drop in four years after a record rally

Data

Investors with a long-term horizon should take a closer look at shares of luxury home goods seller RH, <a href="https://www.fool.com/investing/2025/10/21/why-this-california-based-companys-stock-could-rew/">writes</a>&nbsp;Jeremy Bowman, an analyst at the Motley Fool. The company has faced a number of challenges, leading to a major fall in its share price since the highs reached during the pandemic. But it has several drivers of growth – from expansion into Europe to launching new businesses – that could turn things around, Bowman argues.

The Motley Fool spotlights mid-cap luxury goods retailer RH for patient investors

NeuroSense Therapeutics Ltd.

Noble Capital Markets has initiated coverage of NeuroSense Therapeutics with an “outperform” rating and a target price of $9 per share. Thus, it estimates the micro-cap developer of an amyotrophic lateral sclerosis therapy could rise 620% from current levels. The analysts cite mid-stage trial results of the company’s lead drug PrimeC, which open the way for accelerated registration and earlier commercialization.

Noble initiates on ALS drugmaker NeuroSense with 'outperform', TP for 600% upside


Cleveland-Cliffs Inc.

Shares of mid cap Cleveland-Cliffs, one of the leading players in the U.S. steel industry, jumped in trading today, October 20, up 24% at one point, after the company <a href="https://www.clevelandcliffs.com/investors/news-events/press-releases/detail/686/cleveland-cliffs-reports-third-quarter-2025-results">said</a>&nbsp;it was considering expanding into rare earth metals. Reporting third-quarter results, the company said two of its iron ore deposits show the greatest potential for these minerals and experts are now determining whether the sites could be commercially viable.

Cleveland-Cliffs jumps on plans to 'refocus' rare earth mining efforts

DXP Enterprises, Inc.

Freedom Broker has initiated coverage of DXP Enterprises, a leading small-cap provider of engineering solutions for the industrial sector, with a "buy" at a target price that implies upside of 33% versus the current market price. The company has a balanced business model and stable cash flow, Freedom argues.

Freedom says 'buy' on industrial supplier DXP, citing model, M&A, sector outlook

Rani Therapeutics Holdings, Inc.

Lexaria Bioscience Corp.

Novo Nordisk A/S

Shares of Rani Therapeutics Holdings, a developer of a technology that turns injections into pills, <a href="https://finance.yahoo.com/quote/RANI/">soared</a>&nbsp;nearly 250% on Friday, October 17. Trading volume was almost 60 times the daily average. The company <a href="https://ir.ranitherapeutics.com/news-releases/news-release-details/rani-therapeutics-announces-oversubscribed-603-million-private">delivered</a>&nbsp;two announcements: a collaboration with Japan’s Chugai Pharmaceutical potentially worth $1.09 billion, and a $60.3 million private placement.